

**AMENDMENT FOR DISTRIBUTION 9.0—CONTROLS  
NIMH HUMAN GENETICS INITIATIVE DISTRIBUTION AGREEMENT**

NOW, THEREFORE, it is mutually agreed that the National Institute of Mental Health (NIMH) Human Genetics Initiative Distribution Agreement signed by NIMH, the center for Genetic Studies, and \_\_\_\_\_ as the Receiving Institution is amended to include the following text in paragraph 14 under the section, Acknowledgement for Controls Sample Biomaterials and Clinical Data:

Biomaterials and phenotypic data were obtained from the following projects that participated in the NIMH Controls Genetics Initiative:

**Study 19** – Data and biomaterials were collected for the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), a multi-center, longitudinal (5-8 year) project selected from responses to RFP #NIMH-98-DS-0001, "Treatment for Bipolar Disorder." The project was led by Gary Sachs, M.D., and coordinated by Massachusetts General Hospital in Boston, MA. The NIMH grant number was 2N01MH080001-001.

**Study 23** – Data and biomaterials used in Study 23 were collected by the University of Pittsburgh and funded by an NIMH grant (Genetic Susceptibility in Schizophrenia, MH 56242) to Vishwajit Nimgaonkar, M.D., Ph.D. Additional Principal Investigators on this grant include Smita Deshpande, M.D., Dr. Ram Moanohar Lohia Hospital, New Delhi, India; and Michael Owen, M.D., Ph.D., University of Wales College of Medicine, Cardiff, UK.

**Study 29** – Control subjects from the National Institute of Mental Health Schizophrenia Genetics Initiative (NIMH-GI), data and biomaterials are being collected by the "Molecular Genetics of Schizophrenia II" (MGS-2) collaboration. The investigators and co-investigators are: ENH/Northwestern University, Evanston, IL, MH059571, Pablo V. Gejman, M.D. (Collaboration Coordinator; PI), Alan R. Sanders, M.D.; Emory University School of Medicine, Atlanta, GA, MH59587, Farooq Amin, M.D. (PI); Louisiana State University Health Sciences Center; New Orleans, Louisiana, MH067257, Nancy Buccola APRN, B.C., M.S.N. (PI); University of California-Irvine, Irvine, CA, MH60870, William Byerley, M.D. (PI); Washington University, St. Louis, MO, U01, MH060879, C. Robert Cloninger, M.D. (PI); University of Iowa, Iowa, IA, MH59566, Raymond Crowe M.D. (PI), Donald Black, M.D.; University of Colorado, Denver, CO, MH059565, Robert Freedman, M.D. (PI); University of Pennsylvania, Philadelphia, PA, MH061675, Douglas Levinson, M.D. (PI); University of Queensland, Queensland, Australia, MH059588, Bryan Mowry, M.D. (PI); Mt. Sinai School of Medicine, New York, NY, MH59586, Jeremy Silverman, Ph.D. (PI).

In addition, cord blood samples were collected by Vishwajit Nimgaonkar's group at the University of Pittsburgh, as part of a multi-institutional collaborative research project with Jordan Smoller, M.D., D.Sc., and Pamela Sklar, M.D., Ph.D., Massachusetts General Hospital (grant MH 63420).

**AMENDMENT FOR DISTRIBUTION 9.0—CONTROLS  
NIMH HUMAN GENETICS INITIATIVE DISTRIBUTION AGREEMENT**

**Study 76** – Data and biomaterials were collected as part of a genetics study of schizophrenia supported by National Institutes of Health grant R01MH085548. This study is based at the University of Southern California. The Principal Investigators are Carlos N. Pato, M.D., Ph.D. and Michele T. Pato, M.D.; Co-investigators are Helena Medeiros, MSW, LICSW; James A. Knowles, M.D., Ph.D., Janet L. Sobell, Ph.D.; Stephen Marder, M.D.; Diana Perkins, M.D., MPH; Peter Buckley, M.D.; Christopher Morley, Ph.D.; Dolores Malaspina, M.D.; Evelyn Bromet, Ph.D., Laura Fochtmann, M.D.; Douglas Lehrer, M.D.; Fabio Macciardi, M.D., Ph.D., Marquis Vawter, Ph.D.; Humberto Nicolini, M.D., Ph.D.; Mark Rapaport, M.D.; Jeffrey Rafovsky, M.D., Maria Azevedo, M.D.; Ayman Fanous, M.D.; and Michael Escamilla, M.D. All members of the Genomic Psychiatry Cohort Consortium (GPCC). Other GPCC members are Brooke Sklar, Colony Abbott, Rute Ferreira, Becky L. Kinkead, and Nuria Lanzagorta.

The investigators wish to acknowledge the tremendous efforts of all who contributed to the ascertainment of study subjects and biomaterials (clinical interviewers, phlebotomists, Rutgers University Cell and DNA Repository). We are especially grateful to all study participants.

**Study 77** – Data and samples were collected as part of the International Cohort Collection for Bipolar Disorder (ICCBD), supported by the National Institute of Mental Health grant R01MH-085542 and the Stanley Medical Research Institute. Data collection sites included Partners Healthcare/Massachusetts General Hospital, University of Southern California, Karolinska Institutet, and Cardiff University. Members of the International Cohort Collection for Bipolar Disorder (ICCBD): Jordan W. Smoller (principal investigator); Roy H. Perlis, Phil Hyoun Lee, Victor M. Castro, and Alison G. Hoffnagle (Massachusetts General Hospital); Pamela Sklar (principal investigator), Eli A. Stahl, Shaun M. Purcell, Douglas M. Ruderfer, Alexander W. Charney, and Panos Roussos (Icahn School of Medicine at Mount Sinai); Carlos Pato, Michele Pato, Helen Medeiros, and Janet Sobell, James Knowles (University of Southern California); Nick Craddock, Ian Jones, Liz Forty, Arianna DiFlorio, and Elaine Green (Cardiff University); Lisa Jones and Katherine Dunjowski (Birmingham University); Mikael Landén, Christina Hultman, Anders Juréus, Sarah Bergen, and Oscar Svantesson (Karolinska Institutet); and Steven McCarroll, Jennifer Moran, Jordan W. Smoller, Kimberly Chambert, and Richard A. Belliveau, Jr. (Stanley Center for Psychiatric Research, Broad Institute).

**Study 167** – Data and biomaterials for NIMH Study 167 were collected as part of Biomarker Assessment of Pomaglutmetad on Glutamate Targets: Proof of Clinical Mechanism of Action (POCM), supported by NIMH grant HHSN2712012000071. The principal investigator is Jeffrey A. Lieberman, M.D. The ClinicalTrials.gov identifier is NCT02919774.

**AMENDMENT FOR DISTRIBUTION 9.0— CONTROLS  
NIMH HUMAN GENETICS INITIATIVE DISTRIBUTION AGREEMENT**

**DATED SIGNATURES**

---

Principal Investigator, **PLEASE PRINT**

---

Signature and **Date**, Principal Investigator

---

Signature and **Date**, Receiving Institution's Authorized Representative

---

Signature and **Date**, NIMH Repository & Genomics Resource's Authorized Representative, Rutgers University

---

Signature and **Date**, NIMH's Authorized Representative